During the past decade, Presidio Ospedaliero Garibaldi Nesima conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 2 clinical trials were completed, i.e. on average, 18.2% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 2 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Presidio Ospedaliero Garibaldi Nesima" #1 sponsor was "Azienda Ospedaliera Universitaria Integrata Verona" with 2 trials, followed by "Daiichi Sankyo, Inc." with 2 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 2 trials sponsored, "University of Campania "Luigi Vanvitelli"" with 2 trials sponsored and "Byondis B.V." with 2 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Presidio Ospedaliero Garibaldi Nesima" #1 collaborator was "Agenzia Italiana del Farmaco" with 2 trials as a collaborator, "Azienda Sanitaria-Universitaria Integrata di Udine" with 2 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "German Breast Group" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Presidio Ospedaliero Garibaldi Nesima" are "COVID-19" (2 trials), "Atrial Fibrillation" (1 trials), "First Line Non-Small Cell Lung Cancer" (1 trials), "HER2-Positive Primary Breast Cancer" (1 trials) and "Mesothelioma" (1 trials). Many other conditions were trialed in "Presidio Ospedaliero Garibaldi Nesima" in a lesser frequency.

Most popular intervention types in "Presidio Ospedaliero Garibaldi Nesima" are "Drug" (12 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Avelumab" (3 trials), "Cisplatin" (3 trials), "Gemcitabine" (2 trials), "Pemetrexed" (2 trials) and "Sotrovimab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Presidio Ospedaliero Garibaldi Nesima" are 11 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Presidio Ospedaliero Garibaldi Nesima". undefined are not yet recruiting, 4 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Presidio Ospedaliero Garibaldi Nesima, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Presidio Ospedaliero Garibaldi Nesima, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".